A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology

British Journal of Dermatology

Volumn 141, Issue 2, 1999, Pages 264-273

  Grassberger, M ^a   Baumruker, T ^a   Enz, A ^b   Hiestand, P ^b   Hultsch, T ^b   Kalthoff, F ^a   Schuler, W ^b   Schulz, M ^b   Werner, F J ^a   Winiski, A ^a   Wolff, B ^a   Zenke, G ^b  

^a NOVARTIS RESEARCH INSTITUTE   (Austria)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Allergic contact dermatitis; Anti inflammatory activity; Ascomycin macrolactam derivative; Atopic eczema; Pro inflammatory cytokines; Psoriasis; SDZ ASM 981

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; PHORBOL 13 ACETATE 12 MYRISTATE; PHYTOHEMAGGLUTININ; PIMECROLIMUS;

ANIMAL CELL; ARTICLE; ATOPIC DERMATITIS; CELL PROLIFERATION; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFICACY; GENETIC TRANSCRIPTION; HELPER CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REPORTER GENE; SKIN ALLERGY; T LYMPHOCYTE;

ANIMALS; CALCINEURIN; CELL DIVISION; CELLS, CULTURED; CYTOKINES; DERMATOLOGIC AGENTS; HUMANS; IMMUNOPHILINS; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; SKIN DISEASES; T-LYMPHOCYTES; T-LYMPHOCYTES, HELPER-INDUCER; TACROLIMUS; TACROLIMUS BINDING PROTEINS;

EID: 0032769627     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1999.02974.x     Document Type: Article

References (48)

1. Van Leent EJM, Græber M, Thurston M et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134: 805-9.
2. Queille-Roussel C, Graeber M, Wagenaar A et al. Topical treatment with the anti-inflammoatory macrolactan SDZ ASM 981 inhibits established pickel contact dermatitis. Australas J Dermatol 1997; 38 (Suppl. 2): 55 (Abstr).
3. Mrowietz U, Bräutigam M, Græber M et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998; 139: 992-6.
4. Meingassner J, Grassberger M, Fahrngruber H et al. A potential new anti-inflammatory drug. SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997; 137: 568-76.
5. Enz A, Shapiro G, Chappuis A, Dattler A. Nonradioactive assay for protein phosphatase 2B (calcineurin) activity using a partial sequence of the subunit of cAMP-dependent protein kinase as substrate. Anal Biochem 1994; 216: 147-53.
6. Strong DM, Ahmed AA, Thurman GB, Sell KW. In vitro stimulation of murine spleen cells using a microculture system and a multiple automated sample harvester. J Immunol Methods 1973; 2: 279-91.
7. Meo T. The MLR in the mouse. In: Immunological Methods (Lelkovits I, Pernis B, eds). New York: Academic Press, 1979; 227-39.
8. Chapuis F, Rosenzwajg M, Yagello M et al. Differentiation of human dendritic cells from monocytes in vitro. Eur J Immunol 1997; 27: 431-44.
9. Van Reijsen FC, Bruijnzeel-Komen CAFM, Kalthoff FS et al. Skin-derived aeroallergen-specific T cell clones of Th2 phenotype in patients with atopic dermatitis. J Allergy Clin Immunol 1992; 90: 184-93.
10. Baumann G, Andersen E, Quesniaux V, Eberle MK. Cyclosporine and its analogue SDZ IMM 125 mediate very similar effects on T-cell activation - a comparative analysis in vitro. Transplant Proc 1992; 24: 43-8.
11. Scholz D, Schmidt H, Prieschl EE et al. Inhibition of Fc∈RI-mediated activation of mast cells by 2, 3, 4-trihydropyrimidino[2, 1-a-]-isoquinolines. J Med Chem 1998; 41: 1050-9.
12. Prieschl EE, Novotny V, Csonga R et al. A novel splice variant of the transcription factor Nrfl interacts with the TNFα promoter and stimulates transcription. Nucleic Acids Res 1998; 26: 2291-7.
13. + T cells. J Immunol 1994; 153: 2878-89.
14. Prieschl EE, Pendl GG, Elbe A et al. Induction of the: TNFα promoter in the murine dendritic cell line DC18 and the murine mast cell line CPH is differently regulated. J Immunol 1996; 157: 2645-53
15. Boukamp P, Petrussevska RT, Breitkreutz D et al. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988; 106: 761-71.
16. Jaffe EA, Nachman RL, Becker CC, Minick CR. Culture of human endothelial cells derived from umbilical veins. J Clin Invent 1973; 52: 2745-56.
17. Wolff B, Zsak M, Rabeck C. Immunofluorescence assay for the quantitative and qualitative evaluation of intracellular interleukin-8 in microtiter plates. Anal Biochem 1997; 244: 33-9.
18. Ceska M, Effenberger E, Petchl P, Pursch E. Purification and characterisation of monoclonal and polyclonal antibodies to neutrophil activation peptide (NAP-1). The development of highly sensitive ELISA methods for the determination of NAP-1 and anti-NAP-1 antibodies. Cytokine 1989; 1: 136.
19. Skehan P, Storeng R, Scudiero D, Monks A et al. New colorimetric cylotoxicity assay for anticancer-drug screening, J Natl Cancer Inst 1990; 82: 1107-12.
20. Bruijnzeel-Koomen CAFM, Van Wichen DF, Toonstra J et al. The presence of IgE molecules on epidermal Langerhans cells in patients with atopic dermatitis. Arch Dermatol Res 1986; 278; 199-205.
21. Bieber T, King J. In rfw modulation of the high affinity receptor for IgE (Fc∈RT) on human epidermal Langerhan's cells. Int Arch Allergy Immunol 1992; 99: 204-7.
22. + allergen-specific T lymphocytes in atopic dermatitis lesional skin. J Invest Dermatol 1991 ; 97: 389-94.
23. Thepen T. Langeveld-Wildschut EG, Bihari EC et al. Biphasic response against acroallergen in atopic dermatitis showing a switch from an initial Th2 response into a Th1 response in situ. An immuno-cytochemical study. J Allergy Clin Immunol 1996; 97: 828-37.
24. Ramb-Lindhauer C, Feldmann A, Rolte M, Neumann C. Characterisation of grass pollen reactive T-cell lines derived from lesional atopic skin. Arch Dermatol Res 1991; 283: 71-6.
25. Pene J, Rousset F, Briere F, Chretien I et al. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc Natl Acad Sci USA 1988; 85: 6880-4.
26. Wierenga EA, Backx B, Snoek M et al. Relative contributions of human types 1 and 2 T-helper cell-derived cosinophilotrophic cytokines to development of eosinophilia. Blood 1991; 82: 1471-9.
27. Baker BS, Fry L. The immunology of psoriasis. Br J Dermatol 1992; 126: 1-9.
28. Tiyemura K, Yamamura M, Fivenson DF et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 J cell-mediated response. J Invest Dermatol 1993; 101: 701-5.
29. Schlank JF. Buslau M. Jochum W et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994; 102: 145-9.
30. Bos JD, Hulsebosch HJ, Krieg SR et al. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983; 275; 181-9.
31. Baker B, Swain AE, Fry L, Valdimarsson H. Epidermal T lymphocytes and HLA-DB expression in psoriasis. Br J Dermatol 1984; 110: 555-64.
32. Weinshenker BG, Bass BH, Ebers GC, Rice GPA. Remission of psoriatic lesions with monoclonal CD3 (Orthoclone OKT3) treatment. J Am Acad Dermatol 1989; 20: 1132-3.
33. Prinz J, Braun-Falco O, Meurer M. Chimeric CD4 monoclonal antibody in treatment of generalized pustular psoriasis. Lancet 1991; 338: 320-1.
34. 389 IL-2) suggest a primary immune but not keratinocyte pathogenic basis. Nature Med 1995; 1: 442-7.
35. Stütz A, Grassberger M, Baumann K et al. Immunophilins as drug targets. In: Perspectivesin Medicinal Chemistry (Testa B, Kyburz E, eds). Basel: Helvetica Chimica Acta, 1993; 427-33.
36. Rosen MK, Schreiber SL. Natural products as probes in the study of cellular functions. Investigations of immunophillis. Angew Chem Int Ed 1992; 104; 413-30.
37. Fischer G. Peptidylprolyl-cis/trans-isomerases and their effectors. Angew Chem Ed 1994; 33: 1415-16.
38. Kuy JE. Structure-function relationships in the FK506-binding protein (FKBP) familly of peptidylprolyl cis-trans isomerases. Biochem J 1996; 314: 361-85.
39. Meng X, Lu X, Morris CA et al. A novel human gene PKBP6 is detected in Williams syndrome. Genomics 1998; 52: 130-7.
40. Liu J, Albers MW, Wandless TL et al. Inhibition of T cell signaling by immunophilia-ligand complexes correlate with loss of calcineurin phosphatase activity. Biochemistry 1992; 31: 3896-901.
41. Ullman KS, Northrup JP, Verweij CL, Crabtree GR. Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu Rev Immunol 1990; 8; 421-52.
42. Baumruker T, Pendl G G, Prieschl E E. Gene regulation after F∈RI stimulation in the murine mast cell line CPII. Int Arch Allergy Immunol 1997; 113: 39-41.
43. Armerding D, Van Reijsen FC, Hren A, Mudde GC. Induction of IgE and IgG1 in human B cell cultures with staphylococcal superantigens: Role of helper T cell interaction, resistance to interferon-gamma. Immunobiology 1993; 188: 259-73.
44. Foxwell BMJ, Simon J, Herrero JJ et al. Anti-CD3 antibody-induced expression of both p55 and p75 chains of the high affinity interleukin-2 receptor on human T lymphocytes is inhibited by cyclosporin A. Immunology 1990; 69: 104-9.
45. Dumont FJ, Strauch MJ, Koprak SL et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990; 144: 251-8.
46. Hultsch T, Mueller KD, Meingassner JG, Knop JG. SDZ ASM 981-a novel anti-inflammatory macrolactam-inhibits FC∈RT-mediated mast cell activation. Australas Dermatol 1997; 38 (Suppl. 2): 286 (Abstr.).
47. Segel IH. Enzyme Kinetics. Chichester: John Wiley & Sons, 1975: 170.
48. Dixon M. Determination of enzyme-inhibitor constants. Biochem J 1953; 55; 170-1.